Found and Ozempic: Branded Versus Compounded Semaglutide

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Searching Ozempic next to a telehealth program is really a question about semaglutide and how it is sourced. This independent review sorts that out. Browse the Peptides & GLP-1 education library.

PlexusDx publishes this as editorial analysis. We have no commercial relationship with Found, with the makers of Ozempic, or with any parent company, and no affiliate links or compensation are involved.

Full head-to-head: PlexusDx vs Found →

What follows separates the Ozempic brand from the semaglutide compound, explains what a subscription program like Found can and cannot route, and describes how the receptor-agonist class works. Balanced framing, not a buying recommendation. As of April 2026.

Ozempic, semaglutide, and what gets prescribed

Ozempic is a brand name for semaglutide, an FDA-approved GLP-1 receptor agonist. When shoppers combine it with a telehealth service, the real question is whether they can obtain that compound, a branded product, or a compounded semaglutide preparation. The brand and the molecule are not the same search.

Branded Ozempic versus compounded semaglutide

A branded product like Ozempic comes from a retail pharmacy on an FDA-approved label. Compounded semaglutide comes from a 503A compounding pharmacy against an individual prescription. Both are legitimate routes with different regulatory footing, and which one a program uses shapes availability, format, and cost. Neither route is simply a cheaper version of the other; they are different supply pathways governed by different rules, and a given program may offer one, the other, or both depending on eligibility and current availability. The current details for any program appear on Found's own website.

How the receptor-agonist class works

Semaglutide belongs to the GLP-1 receptor agonist class, which also includes liraglutide and dulaglutide. These compounds engage the single GLP-1 receptor, distinct from the GIP/GLP-1 dual agonist tirzepatide that acts on two incretin pathways. The mechanism is what the class shares, regardless of which brand or program delivers it. Because the class is defined by the receptor it targets rather than by any label, the same underlying pharmacology applies whether a patient receives a branded product or a compounded preparation of the same molecule.

What the STEP program studied

The clinical evidence most associated with semaglutide for weight management is the STEP program, published in The New England Journal of Medicine in 2021. Its trials examined the compound across defined populations and endpoints. STEP describes semaglutide the molecule, not Ozempic the brand or any particular telehealth service, and individual outcomes vary from person to person.

The pathway biology behind every semaglutide prescription

Branded or compounded, semaglutide acts on a metabolic baseline your genes help set. Variants in GLP1R, the very receptor semaglutide targets, and MC4R, a melanocortin receptor central to satiety and energy balance, describe that biology. These are pathway-level markers, not response predictions. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including MC4R variants that map your baseline receptor and appetite-regulation biology before any GLP-1 protocol.

Semaglutide the PlexusDx way

PlexusDx offers semaglutide directly through its Weight Management Protocols, including Semaglutide Injection and Semaglutide Oral, with the genetic context most telehealth-only programs skip. Pairing the pathway insight with the protocol is the differentiator, so the starting point is your baseline biology rather than a brand name you searched for.

No affiliation: PlexusDx is independent of Found and of the makers of Ozempic, and holds no commercial relationship with the programs discussed here.

More from the PlexusDx library: Tirzepatide vs Ozempic, Ozempic For Prediabetes, Ozempic Online, and Ozempic Prescription.

Disclaimer: This article is educational. PlexusDx is not affiliated with Found or with the makers of Ozempic and compares approaches across the GLP-1 telehealth space, including its own Weight Management Protocols. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

Is Ozempic the same as semaglutide?

Ozempic is a brand name for semaglutide, an FDA-approved GLP-1 receptor agonist. Pairing it with a telehealth search usually means asking about access to that compound, either as a branded product or a compounded semaglutide preparation, rather than about the brand alone.

Can a telehealth program provide branded Ozempic?

Programs in this model can route a prescription to a retail pharmacy for an FDA-approved brand product or to a 503A pharmacy for compounded semaglutide. Which pathway applies depends on eligibility and availability, so confirm the current specifics on the brand's own site before assuming.

What did the STEP trials examine?

The STEP program, published in NEJM in 2021, studied semaglutide for weight management across defined populations and endpoints. It describes the compound itself rather than any brand or telehealth service, and individual outcomes vary depending on many personal factors.

Which genes relate to semaglutide's pathway?

Pathway-level variants such as, the receptor semaglutide targets, and MC4R, tied to satiety, describe the baseline biology the compound acts on. They do not predict response. The Precision Peptide Genetic Test reads these markers to add upstream context for your provider conversation.

Continue in the PlexusDx Education Hub. Browse Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.